Millennium Management
XLO icon

Millennium Management’s Xilio Therapeutics XLO Stock Holding History

Millennium Management’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,651
Closed -$37K – 6398
2025
Q1 		$37K Buy
+3,651
New +$45.9K ﹤0.01% 5574
2024
Q4 		– Sell
-1,475
Closed -$16.3K – 6531
2024
Q3 		$16.3K Buy
1,475
+603
+69% +$7.4K ﹤0.01% 5817
2024
Q2 		$11.6K Sell
872
-4,142
-83% -$64.8K ﹤0.01% 5592
2024
Q1 		$75.8K Buy
5,014
+2,846
+131% +$27.5K ﹤0.01% 5628
2023
Q4 		$16.7K Buy
+2,168
New +$42.9K ﹤0.01% 5663
2023
Q3 		– Sell
-921
Closed -$33.8K – 6639
2023
Q2 		$33.8K Sell
921
-275
-23% -$11.7K ﹤0.01% 5552
2023
Q1 		$53K Sell
1,196
-725
-38% -$31.8K ﹤0.01% 5608
2022
Q4 		$72K Sell
1,921
-53
-3% -$1.79K ﹤0.01% 5684
2022
Q3 		$80K Sell
1,974
-1,594
-45% -$61.9K ﹤0.01% 6037
2022
Q2 		$146K Buy
+3,568
New +$189K ﹤0.01% 5779

Other funds holding XLO

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management's XLO Position: Q2 2025 in Review

Millennium Management sold out of Xilio Therapeutics (XLO) in Q2 2025, closing a stake of 3,651 shares — an estimated $37K sold.

Millennium Management first reported a position in XLO in Q2 2022 and held it in 10 quarters. The position peaked at $146K in Q2 2022. 35 funds tracked by Wall St. Rank hold XLO as of Q2 2025.

  • Millennium Management reported no remaining Xilio Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Millennium Management sold 3,651 Xilio Therapeutics shares in Q2 2025, an estimated $37K.
  • Millennium Management first reported a position in Xilio Therapeutics in Q2 2022 and held it in 10 quarters.
  • Millennium Management's Xilio Therapeutics position peaked at $146K in Q2 2022.
  • 35 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2025.

Based on Millennium Management's 13F filing for Q2 2025, filed 14 Aug 2025.